Wu et al. [180] reported that the EZH2 inhibitor could alleviate LN in a NZB/NZW F1 mouse by constraining the excessive IFN-I signaling pathway to reduce the anti-dsDNA autoantibodies production and prolong its survival. Here, EZH2 is linked to lobular neoplasia.